panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
#asco22 plenary session #1. paradigm trial. first prospective study to show os improvement in left-sided mcrc with egfri vs vegfi. unclear why pfs was not extended in 1l. 
Hematology/Oncology fellow @EinsteinMed @MontefioreNYC via @slusom and @USJLiban. Interested in EBM & clinical reasoning. Views are my own.